We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Collaboration to Create New Flow Cytometry Technology for Expanding Cell Biology Market

By Biotechdaily staff writers
Posted on 03 Apr 2008
A long-term partnership has been created to provide integrated flow cytometry systems to scientists conducting research in cell biology, including stem cell research. More...


The companies, Millipore Corp. (Billerica, MA, USA) and Guava Technologies, Inc. (Hayward, CA, USA), will offer scientists improved technical performance, higher quality data, and much greater accessibility to this powerful analytic platform than is currently available.

Flow cytometry is a technique used by scientists to measure changes in protein expression in individual cells that may occur as a consequence of many important factors such as (stem) cell differentiation, disease, aging, cancer development, drug treatment, and toxicity. The combination of Millipore's and Guava's capabilities will integrate instrumentation, reagent kits, validated protocols, and technical support to bring the advantages of flow cytometry to the bench tops of cell biologists.

"Our partnership with Guava creates the potential for us to fundamentally improve the way that cell biology research is conducted,” said Martin Madaus, president and CEO of Millipore. "The combination of Millipore sample prep and reagents with Guava's instrument platform will create an integrated offering, giving scientists a menu of plug and play solutions to help them generate high quality results that advance their research. The collaboration allows us to add considerable value to the highly differentiated antibody portfolio and assay development capabilities that came with our Serologicals acquisition.”

Under the terms of the partnership, Millipore will gain exclusive rights to distribute Guava's nonclinical instrumentation within defined fields in North America, Europe, and other countries in Asia. Furthermore, Millipore will provide field service for all Guava instrumentation in the same geographies. Millipore will also develop co-branded reagent kits specifically for Guava's flow cytometers. Finally, Millipore and Guava Technologies will work together to develop a new generation of instrumentation with enhanced performance and functionality.

"Our two companies have a shared vision of making complex cellular analyses accessible to any scientist. Millipore has significant experience and reach among academic and government researchers and an extensive network of highly qualified service providers throughout the world,” said Lawrence Bruder, president and chief executive officer, Guava Technologies. "With Millipore as our partner, together we can make this vision a reality and significantly increase our global presence and lower the barriers for cell biologists to adopt flow cytometry as a major research tool.”

Guava Technologies developed the first commercially available microcapillary flow-cytometry system. Microcapillary flow cytometers accommodate smaller sample volumes, generate less waste, have lower operating costs, and are easier to set up and run than conventional flow cytometry instrumentation. The collaboration with Millipore will now accelerate delivery of this technology directly into the hands of individual life scientists worldwide. The parties plan to launch co-branded products to the market in July 2008.

Millipore is a life-science company that provides cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, the company collaborates with customers to confront the world's challenging human health issues.

Guava Technologies is a biotechnology and medical device company that develops provider of on-demand, easy-to-use single cell analysis systems. Guava Personal Cell Analysis (PCA) systems, including the Guava PCA, Guava PCA-96, Guava EasyCyte Plus, and Guava EasyCyte Mini systems, are integrated, fully optimized, microcapillary cytometry systems with embedded absolute cell counting capability.


Related Links:
Millipore
Guava Technologies

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.